McCune-Albright syndrome: New insights

Current Opinion in Endocrinology and Diabetes

Volumn 6, Issue 2, 1999, Pages 119-125

  Collins, Michael T ^a   Shenker, Andrew ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; FADROZOLE; GONADORELIN AGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; TAMOXIFEN; TESTOLACTONE;

ADULT; ALBRIGHT SYNDROME; ARTICLE; BONE DISEASE; CAFE AU LAIT SPOT; CELL PROLIFERATION; CHILD; CLINICAL FEATURE; DRUG EFFICACY; EMBRYO DEVELOPMENT; FIBROUS DYSPLASIA; GENE MUTATION; GENETIC ANALYSIS; HORMONE RELEASE; HUMAN; LASER SURGERY; MOLECULAR BIOLOGY; PATHOGENESIS; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0033045841     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199904000-00006     Document Type: Article

References (83)

1. 1 Lee PA, Van Dop C, Migeon CJ: McCune-Albright syndrome: Long-term follow-up. JAMA 1986, 256:2980-2984.
2. 2 Danon M, Crawford JD: The McCune-Albright syndrome. Ergeb Inn Med Kinderheilkd 1987, 55:81-115.
3. 3 Ringel MD, Schwindinger WF, Levine MA: Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine 1996, 75:171-184.
4. 4 Feuillan PP: McCune-Albright syndrome. Curr Ther Endocrinol Metab 1997, 6:235-239. An excellent review focusing on the clinical evaluation and treatment of endocrine abnormalities in children with MAS.
5. Sα protein. J Clin Endocrinol Metab 1994, 79:1128-1134.
6. Sα gene in samples containing a small proportion of abnormal cells and demonstrates that patients with polyostotic fibrous dysplasia alone carry the same molecular defect as those with MAS.
7. S and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989, 340:692-696.
8. Sα could lead to altered osteoblast function in vivo.
9. 9 Yoshimoto K, Iwahana H, Fukuda A, Sano T, Itakura M: Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detectionby polymerase chain reaction-primer-introduced restriction analysis. Cancer 1993, 72:1386-1393.
10. S. J Pediatr 1993, 123:509-518.
11. Sα mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 1994, 79:750-755.
12. 12 Bianco P, Kuznetsov SA, Riminucci M, Fisher LW, Spiegel AM, Robey PG: Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsα-mutated skeletal progenitor cells. J Clin Invest 1998, 101:1737-1744. This important paper describes the development of the first in vivo model system to study the bone biology, pathology, and treatment of fibrous dysplasia. The use of clonal skeletal progenitor cells is likely to have broad applications for the study of human bone disease.
13. 13 Cabral CE, Guedes P, Fonesca T, Rezende JF, Cruz Junior LC, Smith J: Polyostotic fibrous dysplasia associated with intramuscular myxomas: Mazabraud's syndrome. Skeletal Radiol 1998, 27:278-282.
14. 14 Russo D, Arturi F, Wicker R, Chazenbalk GD, Schlumberger M, DuVillard J-AD, Caillou B, Monier R, Rapoport B, Filetti S, Suarez HG: Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1995, 80:1347-1351.
15. Sα protein in growth hormone-secreting tumors. J Clin Endocrinol Metab 1998, 83:4386-4390.
16. Sα gene. Hum Mol Genet 1995, 4:1675-1676.
17. Sα.
18. 18 Fragoso MCBV, Latronico AC, Carvalho FM, Zerbini MCN, Marcondes JAM, Araujo LMB, Lando VS, Frazzatto ET, Mendonca BB, Villares SMF: Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J Clin Endocrinol Metab 1998, 83:2074-2078.
19. 19 Cummings EA, Salisbury SR, Givner ML, Rittmaster RS: Testolactone-associated high androgen levels, a pharmacologic effect or a laboratory artifact? J Clin Endocrinol Metab 1998, 83:784-787.
20. 20 Nunez SB, Feuillan PP, Jones J, Cutler GB Jr: The aromatase inhibitor fadrozole is not an effective treatment for the precocious puberty in the McCune-Albright syndrome. Program and Abstracts, The Endocrine Society 79th Annual Meeting 1997, p. 413.(Abstract)
21. 21 Eugster E, Shankar R, Feezle LK, Pescovitz OH: Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. J Pediatr Endocrinol Metab 1999, (In Press) The authors describe their successful three year experience using tamoxifen to treat precocious puberty in one girl with MAS. Pubertal progression was arrested, growth velocity normalized, and no adverse effects were noted.
22. 22 Schmidt H, Kiess W: Secondary central precocious puberty in a girl with McCune-Albright syndrome responds to treatment with GnRH analogue. J Pediatr Endocrinol Metab 1998, 11:77-81.
23. 23 Escobar ME, Gryngarten M, Domené H, Ropelato G, López MR, Bergadá C: Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome. J Pediatr Adolesc Gynecol 1997, 10:147-151.
24. 24 Seligman SP: McCune-Albright syndrome. J Bellevue Obstet Gynecol Soc 1992, 8:56.(Abstract)
25. 25 Mastorakos G, Mitsiades NS, Doufas AG, Koutras DA: Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. Thyroid 1997, 7:433-439. An excellent review of the literature on thyroid abnormalities in MAS patients.
26. 3 toxicosis in McCune-Albright syndrome. Horm Res 1997, 50:105-106.
27. 27 Spambalg D, Sharifi N, Elisei R, Gross JL, Medeiros-Neto G, Fagin JA: Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab 1996, 81:3898-3901.
28. 28 Michiels FM, Caillou B, Talbot M, Dessarps-Freichey F, Maunoury MT, Schlumberger M, Mercken L, Monier R, Feunteun J: Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands of transgenic mice. Proc Natl Acad Sci USA 1994, 91:10488-10492.
29. 29 Zeiger MA, Saji M, Gusev Y, Westra WH, Takiyama Y, Dooley WC, Kohn LD, Levine MA: Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice. Endocrinology 1997, 138:3133-3140.
30. 30 Ivan M, Ludgate M, Gire V, Bond JA, Wynford-Thomas D: An amphotropic retroviral vector expressing a mutant gsp oncogene: effects on human thyroid cells in vitro. J Clin Endocrinol Metab 1997, 82:2702-2709.
31. S-α gene mutations in the pathogenesis of toxic thyroid adenomas - a note of caution. J Clin Endocrinol Metab 1996, 81:2783-2785.
32. 32 Sherman SI, Ladenson PW: Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J Endocrinol Invest 1992, 15:185-190.
33. Sα mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998, 83:1604-1610.
34. 34 Chen CC, Czerwiec FS, Feuillan PP: Visualization of fibrous dysplasia during somatostatin receptor scintigraphy. J Nucl Med 1998, 39:238-240.
35. 35 Hammami MM, AL-Zahrani A, Butt A, Vencer LJ, Hussain SS: Primary hyperparathyroidism-associated polyostotic fibrous dysplasia: Absence of McCune-Albright syndrome mutations. J Endocrinol Invest 1997, 20:552-558.
36. 36 LaBagnara J, Yuppa F, Klein MH: Fibrous dysplasia of the middle turbinate with primary hyperparathyroidism. Ear Nose Throat J 1998, 77:552-553.
37. 37 Zung A, Chalew SA, Schwindinger WF, Levine MA, Philip M, Jara A, Counts DR, Kowarski AA: Urinary cyclic adenosine 3′,5′-monophosphate response in McCune-Albright syndrome: clinical evidence for altered renal adenylate cyclase activity. J Clin Endocrinol Metab 1995, 80:3576-3581.
38. 38 Whyte MP: Hypophosphatemic bone disease in McCune-Albright syndrome. Calcif Tissue Int 1996, 59:224.(Abstract)
39. Sα gene: site-specific patterns and recurrent histological hallmarks. Pathology 1999, 187:249-258.
40. 40 Thorogood P: The head and face. In Embryos, Genes and Birth Defects, edited by Thorogood P. Chichester: John Wiley & Sons; 1997:197-229.
41. 41 Szwajkun P, Chen Y-R, Yeow VKL, Breidahl AF: The "Taiwanese giant": hormonal and genetic influences in fibrous dysplasia. Ann Plast Surg 1998, 41:75-80.
42. 42 Katz BJ, Nerad JA: Ophthalmic manifestations of fibrous dysplasia. A disease of children and adults. Ophthalmology 1998, 105:2207-2215. This paper reviews major signs and symptoms, pattern of bone involvement, radiographic appearance of lesions, and management of visual loss due to optic nerve compression.
43. 43 Bocca G, de Vries J, Cruysberg JRM, Boers GHJ, Monnens LAH: Optic neuropathy in McCune-Albright syndrome: an indication for aggressive treatment. Acta Paediatr 1998, 87:599-600.
44. 44 Edelstein C, Goldberg RA, Rubino G: Unilateral blindness after ipsilateral prophylactic transcranial optic canal decompression for fibrous dysplasia. Am J Ophthalmol 1998, 126:469-471.
45. 45 Stanton RP, Montmomery BE: Fibrous dysplasia. Orthopedics 1996, 19:679-685.
46. 46 Shih HN, Chen YJ, Huang TJ, Hsu KY, Hsu RW: Treatment of fibrous dysplasia involving the proximal femur. Orthopedics 1998, 21:1263-1266.
47. 47 Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ: Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998, 13:1668-1678.
48. 48 Liens D, Delmas PD, Meunier PJ: Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994, 343:953-954.
49. 49 Chapurlat RD, Delmas PD, Liens D, Meunier PJ: Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997, 12:1746-1752. This is the best study to date on the medical treatment of FD with a bisphosphonate. Results represent an extension of the promising findings reported earlier by this group (Lancet 1994, 343:953-954).
50. 50 Pfeilschifter J, Ziegler R: Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome. Med Klin 1998, 93:352-359.
51. 51 Weinstein RS: Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density. J Bone Miner Res 1997, 12:1314-1315.
52. 52 Bishop NJ, Plotkin H, Travers R, Lanoue G, Rauch F, Glorieux FH: Effects of two years of pamidronate treatment in children with polyostotic fibrous dysplasia [abstract]. Bone 1998, 22:61S.
53. 53 Czerwiec FS, Collins M, Feuillan P, Shenker A: Further study of the therapy for fibrous dysplasia is necessary. J Bone Miner Res 1997, 12:2128-2130.
54. 54 Shimbashi T, Kamide R, Hashimoto T: Long-term follow-up in treatment of solar lentigo and café-au-lait macules with Q-switched ruby laser. Aesthetic Plast Surg 1997, 21:445-448.
55. 55 Raulin C, Schönermark MP, Greve B, Werner S: Q-switched ruby laser treatment of tattoos and benign pigmented skin lesions: a critical review. Ann Plast Surg 1998, 41:555-565.
56. Sα · GTPγS. Science 1997, 278:1907-1916.
57. Sα. Science 1997, 278:1943-1947.
58. 58 Lader AS, Xiao Y-F, Ishikawa Y, Cui Y, Vatner DE, Vatner SF, Homcy CJ, Cantiello HF: Cardiac Gsα overexpression enhances L-type calcium channels through an adenylyl cyclase independent pathway. Proc Natl Acad Sci USA 1998, 95:9669-9674.
59. 59 Gaiddon C, Boutiflier A-L, Monnier D, Mercken L, Loeffler J-P: Genomic effects of the putative oncogene Gαs: chronic transcriptional activation of the c-fos proto-oncogene in endocrine cells. J Biol Chem 1994, 269:22663-22671.
60. 60 Montminy M: Transcriptional regulation by cyclic AMP. Annu Rev Biochem 1997, 66:807-822.
61. 201 mutation exhibit increased growth and reduced differentiation in culture.
62. 62 Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Robey PG: Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. Am J Pathol 1997, 151:1587-1600. The authors use histological, histochemical, immunochemical, and in situ hybridization methods to study the properties of bone specimens from six MAS patients. Dysplastic bone is found to contain an abnormal complement of bone matrix proteins and osteoblasts exhibit a retracted shape that may be related to excess cAMP production.
63. 63 Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka T, Kishimoto T, Okada S: Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 1996, 998:30-35.
64. 64 Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998, 128:127-137.
65. 65 Modrowski D, Godet D, Marie PJ: Involvement of interleukin 1 and tumor necrosis factor alpha as endogenous growth factors in human osteoblastic cells. Cytokine 1995, 7:720-726.
66. 66 Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 17:165-176.
67. 67 Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
68. 68 Roger PP, Reuse S, Maenhaut C, Dumont JE: Multiple facets of the modulation of growth by cAMP. Vitam Horm 1995, 51:59-191.
69. 69 Dremier S, Pohl V, Poteet-smith C, Roger PP, Corbin J, Ove Doskeland S, Dumont JE, Maenhaut C: Activation of cyclic AMP-dependent kinase is required but may not be sufficient to mimic cyclic AMP-dependent DNA synthesis and thyroglobulin expression in dog thyroid cells. Mol Cell Biol 1997, 17:6717-6726.
70. 70 Depoortere F, Van Keymeulen A, Lukas J, Costagliola S, Bartkova J, Dumont JE, Bartek J, Roger PP, Dremier S: A requirement for cyclin D3-cyclin-dependent kinase (cdk)-4 assembly in the cyclic adenosine monophosphate-dependent proliferation of thyrocytes. J Cell Biol 1998, 140:1427-1439. This paper and others cited from the same group provide an excellent overview of what is known about the stimulatory effects of cAMP on proliferation of endocrine cells.
71. 71 Nemoz G, Sette C, Hess M, Muca C, Vallar L, Conti M: Activation of cyclic nucleotide phosphodiesterases in FRTL-5 thyroid cells expressing a constitutively active Gs alpha. Mol Endocrinol 1995, 9:1279-1287.
72. Sα (Q227L) show enhanced hormone secretion and proliferation. Mol Cell Endocrinol 1997, 127:41-47.
73. 73 Fournes B, Monier R, Michiels F, Milgrom E, Misrahi M, Feunteun J: Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells. Oncogene 1998, 16:985-990.
74. Sα in somatotroph adenomas are associated with increased phosphodiesterase activity. These data are consistent with those obtained in transfected cells, and suggest that the in vivo phenotype of gsp mutant cells may be modified by increased cAMP degradation and other counterregulatory pathways.
75. S. Mol Cell Endocrinol 1998, 138:137-142.
76. Sα in Drosophila. Proc Natl Acad Sci USA 1996, 93:14542-14547.
77. S-induced neurodegeneration in Caenorhabditis elegans. J Neurosci 1998, 18:2871-2880.
78. 78 Korswagen HC, van der Linden AM, Plasterk RHA: G protein hyperactivation of the Caenorhabditis elegans adenylyl cyclase SGS-1 induces neuronal degeneration. EMBO J 1998, 17:5059-5065.
79. 79 de Rooij J, Zwartkruis FJT, Verheijen MHG, Cool RH, Nijman SMB, Wittinghofer A, Bos JL: Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396:474-477.
80. 80 Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM: A family of cAMP-binding proteins that directly activate Rap1. Science 1998, 282:2275-2279.
81. 81 Jüppner H, Schipani E, Bastepe M, Cole DEC, Lawson ML, Mannstadt M, Hendy GN, Plotkin H, Koshiyama H, Koh T, Crawford JD, Olsen BR, Vikkula M: The gene responsible for pseudohypoparathyroidism type Ib is paternally imprinted and maps in four unrelated kindreds to chromosome 20q13.3. Proc Natl Acad Sci USA 1998, 95:11798-11803.
82. Sα gene was disrupted and demonstrates that the gene is imprinted (not transcribed from the paternal allele) in certain tissues. Tissue-specific imprinting is a poorly understood epigenetic phenomenon and the implications for MAS remain to be determined.
83. Sα gene may be significantly more complex than previously suggested.